multiple myeloma
Conditions
Interventions
Olanzapine group Olanzapine
5mg PO on days 1 to 5 Aprepitant
125 mg PO on day 1, 80 mg PO on days 2 to 3 Palonosetron
0.75mg IV on day 1 Dexamethasone
6.6 mg IV on day 1, 4 mg PO on days 2 to 4
Standard precaution proup Aprepitant
6.6 mg IV on day 1, 4 mg PO on days 2 to 4
Sponsors
Hitachi general hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who undergo autologous stem cell transplantation 2)ECOG-Performance Status (PS) is 0-2 3)Patients who are not allergic to Olanzapine 4)Patients who don't have a history of diabetes 5)Patient who provided written consents for this study
Exclusion criteria
Exclusion criteria: 1)Uncontrolled active infection. 2)Active gastrointestinal ulcer. 3)Serious psychiatric illness. 4)Patient who is judged to be medically unfit by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate for the delayed phase (24-120 hours), defined as no emetic episodes and no use of rescue medication | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate for the acute phase (0-24 hours) and the overall phase (0-120 hours). Complete control rate for the acute, delayed and overall phase. | — |
Countries
Japan
Contacts
Public ContactMisayo Shimizu
Hitachi general hospital hematology,oncology
Outcome results
None listed